Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study (2023)
Attributed to:
The Durability of immune Responses to vaccination against SARS-CoV-2 and its Variants.
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2468-1253(22)00389-2
Publication URI: http://dx.doi.org/10.1016/s2468-1253(22)00389-2
Type: Journal Article/Review
Parent Publication: The Lancet Gastroenterology & Hepatology
Issue: 2